Literature DB >> 1505608

Change in glucose metabolism after long-term treatment with deflazacort and betamethasone.

A Bruno1, G Pagano, L Benzi, G Di Ciani, V Spallone, G Calabrese, A Passeri.   

Abstract

We have compared the long-term effects of different corticosteroids on glucose metabolism by carrying out a 75 g oral glucose tolerance test in 27 subjects before and after the administration of deflazacort or betamethasone for two months in random balanced sequence. Fasting plasma glucose and insulin concentrations were significantly higher after betamethasone, whereas deflazacort increased only fasting plasma insulin. After oral glucose there were significant increases in blood glucose and insulin after betamethasone compared with deflazacort. These results suggest that the degree of glucose intolerance and insulin resistance depends on the steroid used and on the dose given, although long-term treatment with deflazacort has a smaller effect on glucose metabolism than betamethasone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505608     DOI: 10.1007/bf02280753

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Influence of adrenal cortical steroids on carbohydrate metabolism in man.

Authors:  J W CONN; S S FAJANS
Journal:  Metabolism       Date:  1956-03       Impact factor: 8.694

2.  Deflazacort versus prednisone diabetogenic effect evaluated by glucose clamp and compartmental analysis.

Authors:  G Pagano; P Cavallo-Perin; A Bruno; A Lombardi; A Ozello; A M Dall'Omo; B Imbimbo
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

3.  The effects of acute and chronic dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes.

Authors:  J M Olefsky; J Johnson; F Liu; P Jen; G M Reaven
Journal:  Metabolism       Date:  1975-04       Impact factor: 8.694

4.  Effect of glucocorticoids on hexose transport in rat adipocytes. Evidence for decreased transporters in the plasma membrane.

Authors:  C Carter-Su; K Okamoto
Journal:  J Biol Chem       Date:  1985-09-15       Impact factor: 5.157

5.  Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects.

Authors:  G Pagano; A Lombardi; G M Ferraris; B Imbimbo; P Cavallo Perin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Receptors for peptide hormones. New insights into the pathophysiology of disease states in man.

Authors:  C R Kahn; K Megyesi; R S Bar; R C Eastman; J S Flier
Journal:  Ann Intern Med       Date:  1977-02       Impact factor: 25.391

7.  An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects.

Authors:  G Pagano; P Cavallo-Perin; M Cassader; A Bruno; A Ozzello; P Masciola; A M Dall'omo; B Imbimbo
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.

Authors:  R A Rizza; L J Mandarino; J E Gerich
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

9.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

10.  Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone.

Authors:  G Pagano; A Bruno; P Cavallo-Perin; L Cesco; B Imbimbo
Journal:  Arch Intern Med       Date:  1989-05
View more
  6 in total

1.  Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action.

Authors:  Kevin C J Yuen; Patricia A McDaniel; Matthew C Riddle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-08       Impact factor: 3.478

2.  The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Authors:  Laura C McAdam; Amanda L Mayo; Benjamin A Alman; W Douglas Biggar
Journal:  Acta Myol       Date:  2012-05

3.  Deflazacort versus other glucocorticoids: a comparison.

Authors:  Surajit Nayak; Basanti Acharjya
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

Review 4.  Deflazacort. A review of its pharmacological properties and therapeutic efficacy.

Authors:  A Markham; H M Bryson
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

5.  Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man.

Authors:  A Bruno; P Carucci; M Cassader; P Cavallo-Perin; G Gruden; C Olivetti; G Pagano
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.

Authors:  Luca Parente
Journal:  BMC Pharmacol Toxicol       Date:  2017-01-05       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.